Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 617-627

  Kaliszczak, MacIej ^a,d   Antonow, Dyeison ^b   Patel, Katan I ^a   Howard, Philip ^b   Jodrell, Duncan I ^a,e   Thurston, David E ^b,c   Guichard, Sylvie M ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ABCG2; Glutathione; MRP1; P glycoprotein; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; DRG 16; DSB 120; ELB 21; GAMMA GLUTAMYLCYSTEINE; GAMMA HISTONE H2AX; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HISTONE H2AX; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; SG 2003; SG 2781; SG 2796; SG 2797; SG 2819; SG 2820; SG 2823; SG 2825; SG 2897; SG 2900; SG 2901; SG 2902; SJG 136; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; AROMATIC RING; AROMATICITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSION; DNA CROSS LINKING; DNA DAMAGE; DRUG BINDING; DRUG DNA BINDING; DRUG PENETRATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TRANSPORT; ELECTROPHILICITY; ELECTROSTATIC POTENTIAL; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; LIPOPHILICITY; MOLECULAR WEIGHT; POLAR SURFACE AREA; STRUCTURE ACTIVITY RELATION; SURFACE CHARGE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZODIAZEPINES; CELL LINE, TUMOR; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649683448     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9225-x     Document Type: Article

References (41)

1. SV Ambudkar S Dey CA Hrycyna M Ramachandra I Pastan MM Gottesman 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 361 398 1:CAS:528:DyaK1MXjtVejtLo%3D 10.1146/annurev.pharmtox.39.1.361 10331089 (Pubitemid 29222564)
2. JA Silverman 1999 Multidrug-resistance transporters Pharm Biotechnol 12 353 386 1:CAS:528:DC%2BD3cXkslylurc%3D 10.1007/0-306-46812-3-13 10742982
3. JF Deeken W Loscher 2007 The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin Cancer Res 13 6 1663 1674 1:CAS:528:DC%2BD2sXivV2gtrg%3D 10.1158/1078-0432.CCR-06-2854 17363519 (Pubitemid 46952931)
4. HR Mellor R Callaghan 2008 Resistance to chemotherapy in cancer: a complex and integrated cellular response Pharmacology 81 4 275 300 1:CAS:528:DC%2BD1cXlsFOgs70%3D 10.1159/000115967 18259091 (Pubitemid 351666917)
5. JA Hartley VJ Spanswick N Brooks PH Clingen PJ McHugh D Hochhauser, et al. 2004 SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity Cancer Res 64 18 6693 6699 1:CAS:528:DC%2BD2cXnsFOksrw%3D 10.1158/0008-5472.CAN-03-2941 15374986 (Pubitemid 39297932)
6. SJ Gregson PW Howard JA Hartley NA Brooks LJ Adams TC Jenkins, et al. 2001 Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity J Med Chem 44 5 737 748 1:CAS:528:DC%2BD3MXmvVOisA%3D%3D 10.1021/jm001064n 11262084 (Pubitemid 32171670)
7. YY Janjigian W Lee MG Kris VA Miller LM Krug CG Azzoli, et al. 2010 A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors Cancer Chemother Pharmacol 65 5 833 838 1:CAS:528:DC%2BC3cXit1GmtL0%3D 10.1007/s00280-009-1088-4 19672598
8. MC Alley MG Hollingshead CM Pacula-Cox WR Waud JA Hartley PW Howard, et al. 2004 SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations Cancer Res 64 18 6700 6706 1:CAS:528:DC%2BD2cXnsFOksr0%3D 10.1158/0008-5472.CAN-03-2942 15374987 (Pubitemid 39297933)
9. SM Guichard JS Macpherson DE Thurston DI Jodrell 2005 Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136 Eur J Cancer 41 12 1811 1818 1:CAS:528:DC%2BD2MXns1WitLw%3D 10.1016/j.ejca.2005.04.026 16046116 (Pubitemid 41132645)
10. D Antonow M Kaliszczak GD Kang M Coffils AC Tiberghien N Cooper, et al. 2010 Structure-activity relationships of monomeric C2-aryl pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD) antitumor agents J Med Chem 53 7 2927 2941 1:CAS:528:DC%2BC3cXjtVygsLs%3D 10.1021/jm901722v 20218628
11. AM Burger PM Loadman DE Thurston R Schultz HH Fiebig MC Bibby 2007 Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119) J Chemother 19 1 66 78 1:CAS:528:DC%2BD2sXislSgsrc%3D 17309854
12. Thurston DE. Advances in the Study of Pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD) Antitumour Antibiotics: molecular aspects of anticancer drug-DNA interactions. London: Macmillan; 1993. p. 54-88.
13. D Hochhauser T Meyer VJ Spanswick J Wu PH Clingen P Loadman, et al. 2009 Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors Clin Cancer Res 15 6 2140 2147 1:CAS:528:DC%2BD1MXjtF2rurg%3D 10.1158/1078-0432.CCR-08-1315 19276288
14. D Antonow N Cooper PW Howard DE Thurston 2007 Parallel synthesis of a novel C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) library J Comb Chem 9 3 437 445 1:CAS:528:DC%2BD2sXjs1Sktb0%3D 10.1021/cc0601332 17397227
15. SJ Gregson PW Howard KE Corcoran TC Jenkins LR Kelland DE Thurston 2001 Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2, 1-c][1, 4]benzodiazepine dimer Bioorg Med Chem Lett 11 21 2859 2862 1:CAS:528:DC%2BD3MXnsVKls7w%3D 10.1016/S0960-894X(01)00560-1 11597416
16. KG Louie BC Behrens TJ Kinsella TC Hamilton KR Grotzinger WM McKoy, et al. 1985 Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine Cancer Res 45 5 2110 2115 1:CAS:528:DyaL2MXktF2itb8%3D 3986765
17. M Nakagawa E Schneider KH Dixon J Horton K Kelley C Morrow, et al. 1992 Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells Cancer Res 52 22 6175 6181 1:CAS:528:DyaK3sXjt1KgtQ%3D%3D 1358431
18. P Skehan R Storeng D Scudiero A Monks J McMahon D Vistica, et al. 1990 New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 13 1107 1112 1:CAS:528:DyaK3cXltVylsL8%3D 10.1093/jnci/82.13.1107 2359136
19. P Artursson J Karlsson 1991 Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem Biophys Res Commun 175 3 880 885 1:CAS:528:DyaK3MXhslOrt7c%3D 10.1016/0006-291X(91)91647-U 1673839
20. G Szakacs JK Paterson JA Ludwig C Booth-Genthe MM Gottesman 2006 Targeting multidrug resistance in cancer Nature reviews 5 3 219 234 1:CAS:528:DC%2BD28XhvFOlsr8%3D 10.1038/nrd1984 16518375 (Pubitemid 43336035)
21. IJ Hidalgo TJ Raub RT Borchardt 1989 Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability Gastroenterology 96 3 736 749 1:STN:280:DyaL1M7itFeqsg%3D%3D 2914637
22. DS Samiulla VV Vaidyanathan PC Arun G Balan M Blaze S Bondre, et al. 2005 Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery Mol Divers 9 1-3 131 139 1:CAS:528:DC%2BD2MXhslelsLw%3D 10.1007/s11030-005-1297-7 15789560 (Pubitemid 40394847)
23. Burkert U, Allinger NL. Molecular MechanicsACS Monograph 177. Washington, DC: American Chemical Society; 1982.
24. A Seelig 1998 A general pattern for substrate recognition by P-glycoprotein Eur J Biochem 251 1-2 252 261 1:CAS:528:DyaK1cXnvV2rsg%3D%3D 10.1046/j.1432-1327.1998.2510252.x 9492291 (Pubitemid 28081437)
25. A Seelig R Gottschlich RM Devant 1994 A method to determine the ability of drugs to diffuse through the blood-brain barrier Proc Natl Acad Sci USA 91 1 68 72 1:CAS:528:DyaK2cXpsVGqtw%3D%3D 10.1073/pnas.91.1.68 8278409 (Pubitemid 24018644)
26. RT Dorr JD Liddil MJ Soble 1986 Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells Invest New Drugs 4 4 305 313 1:CAS:528:DyaL2sXktFOgtb0%3D 10.1007/BF00173503 3583642
27. R Didziapetris P Japertas A Avdeef A Petrauskas 2003 Classification analysis of P-glycoprotein substrate specificity J Drug Target 11 7 391 406 1:CAS:528:DC%2BD2cXjtFOjs7k%3D 10.1080/10611860310001648248 15203928 (Pubitemid 38455825)
28. JS Lee K Paull M Alvarez C Hose A Monks M Grever, et al. 1994 Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen Mol Pharmacol 46 4 627 638 1:CAS:528:DyaK2MXitVantbw%3D 7969041
29. M Essodaigui HJ Broxterman A Garnier-Suillerot 1998 Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein Biochemistry 37 8 2243 2250 1:CAS:528:DyaK1cXotFGmtw%3D%3D 10.1021/bi9718043 9485370 (Pubitemid 28119297)
30. A Seelig E Landwojtowicz 2000 Structure-activity relationship of P-glycoprotein substrates and modifiers Eur J Pharm Sci 12 1 31 40 1:CAS:528:DC%2BD3cXot1yiu7w%3D 10.1016/S0928-0987(00)00177-9 11121731
31. T Osterberg U Norinder 2001 Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/logP and ACD/ChemSketch descriptors Eur J Pharm Sci 12 3 327 337 1:CAS:528:DC%2BD3cXoslGhtbk%3D 10.1016/S0928-0987(00)00189-5 11113652
32. MV Varma K Sateesh R Panchagnula 2005 Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport Mol Pharmacol 2 1 12 21 1:CAS:528:DC%2BD2cXhtVSmu7vF 10.1021/mp0499196 (Pubitemid 40314725)
33. S Vautier L Lacomblez H Chacun V Picard F Gimenez R Farinotti, et al. 2006 Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse Eur J Pharm Sci 27 2-3 167 174 1:CAS:528:DC%2BD2MXhtlCktbfP 10.1016/j.ejps.2005.09.009 16263252 (Pubitemid 41831252)
34. T Miyama H Takanaga H Matsuo K Yamano K Yamamoto T Iga, et al. 1998 P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier Antimicrob Agents Chemother 42 7 1738 1744 1:CAS:528:DyaK1cXktlKgsrg%3D 9661014 (Pubitemid 28311572)
35. E Mechetner A Kyshtoobayeva S Zonis H Kim R Stroup R Garcia, et al. 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin Clin Cancer Res 4 2 389 398 1:CAS:528:DyaK1cXhtlSmsbs%3D 9516927
36. H Nakagawa H Saito Y Ikegami S Aida-Hyugaji S Sawada T Ishikawa 2006 Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer Cancer Lett 234 1 81 89 1:CAS:528:DC%2BD28Xit12itb8%3D 10.1016/j.canlet.2005.05.052 16309825 (Pubitemid 43343942)
37. R Clark ID Kerr R Callaghan 2006 Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter Br J Pharmacol 149 5 506 515 1:CAS:528:DC%2BD28XhtFeru7vO 10.1038/sj.bjp.0706904 16981002 (Pubitemid 44658511)
38. A Cheung E Struble J He C Yang E Wang DE Thurston, et al. 2005 Direct liquid chromatography determination of the reactive imine SJG-136 (NSC 694501) J Chromatogr B Analyt Technol Biomed Life Sci 822 1-2 10 20 1:CAS:528: DC%2BD2MXmsVOnurY%3D 15994138
39. CM Kruijtzer JH Beijnen H Rosing 2002 ten Bokkel Huinink WW, Schot M, Jewell RC, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J Clin Oncol 20 13 2943 2950 1:CAS:528:DC%2BD38Xlslyrt7w%3D 10.1200/JCO.2002.12. 116 12089223 (Pubitemid 34728888)
40. HM McDaid S Mani HJ Shen F Muggia D Sonnichsen SB Horwitz 2002 Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study Clin Cancer Res 8 7 2035 2043 1:CAS:528: DC%2BD38XmtVWit7s%3D 12114401
41. SE Bates WY Medina-Perez G Kohlhagen S Antony T Nadjem RW Robey, et al. 2004 ABCG2 mediates differential resistance to SN-38 (7-ethyl-10- hydroxycamptothecin) and homocamptothecins J Pharmacol Exp Ther 310 2 836 842 1:CAS:528:DC%2BD2cXmtVykt7g%3D 10.1124/jpet.103.063149 15075385 (Pubitemid 38988932)